Literature DB >> 31773173

[Malignant melanoma].

Georg Lodde1, Lisa Zimmer2, Elisabeth Livingstone2, Dirk Schadendorf2,3,4, Selma Ugurel2.   

Abstract

Malignant melanoma is an aggressive skin cancer that originates from cells of the melanocytic lineage and is associated with an invasive growth pattern and early spread. Besides endogenous risk factors such as fair skin type or genetic disposition for the formation of multiple nevi, exposure to ultraviolet light is the most important exogenous risk factor. Treatment of patients with primary tumors includes the complete excision of the primary lesion with appropriate safety margins and in patients with an increased risk of metastasis sentinel lymph node excision. Prognostically significant parameters are the Breslow invasion depth, ulceration of the primary lesion, and sentinel lymph node status. Systemic therapy plays an important role in the adjuvant setting and for inoperable tumors. Depending on the indication and the molecular profile of the tumor tissue, immune checkpoint inhibitors or targeted kinase inhibitors can be used and may result in a significant prolongation of survival times.

Entities:  

Keywords:  Margins of excision; Nevi and melanomas; Sentinel lymph node biopsy; Skin neoplasms; Ultraviolet rays

Mesh:

Year:  2020        PMID: 31773173     DOI: 10.1007/s00105-019-04514-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  29 in total

1.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

Authors:  Dirk Schadendorf; F Stephen Hodi; Caroline Robert; Jeffrey S Weber; Kim Margolin; Omid Hamid; Debra Patt; Tai-Tsang Chen; David M Berman; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

2.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

Review 3.  Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

Authors:  Selma Ugurel; Joachim Röhmel; Paolo A Ascierto; Keith T Flaherty; Jean Jacques Grob; Axel Hauschild; James Larkin; Georgina V Long; Paul Lorigan; Grant A McArthur; Antoni Ribas; Caroline Robert; Dirk Schadendorf; Claus Garbe
Journal:  Eur J Cancer       Date:  2017-08-23       Impact factor: 9.162

4.  Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

Authors:  Jean Jacques Grob; Dirk Schadendorf; Paul Lorigan; Paolo Ascierto; James Larkin; Paul Nathan; Caroline Robert; Axel Hauschild; Jeffrey Weber; Adil Daud; Omid Hamid; Reinhard Dummer; Johan Hansson; Christoph Hoeller; Jacob Schachter; Alexander C J Van Akkooi; Claus Garbe
Journal:  Eur J Cancer       Date:  2017-12-07       Impact factor: 9.162

5.  Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.

Authors:  Lisa Zimmer; Simone M Goldinger; Lars Hofmann; Carmen Loquai; Selma Ugurel; Ioannis Thomas; Maria I Schmidgen; Ralf Gutzmer; Jochen S Utikal; Daniela Göppner; Jessica C Hassel; Friedegund Meier; Julia K Tietze; Andrea Forschner; Carsten Weishaupt; Martin Leverkus; Renate Wahl; Ursula Dietrich; Claus Garbe; Michael C Kirchberger; Thomas Eigentler; Carola Berking; Anja Gesierich; Angela M Krackhardt; Dirk Schadendorf; Gerold Schuler; Reinhard Dummer; Lucie M Heinzerling
Journal:  Eur J Cancer       Date:  2016-04-13       Impact factor: 9.162

6.  Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Authors:  Michael A Davies; Philippe Saiag; Caroline Robert; Jean-Jacques Grob; Keith T Flaherty; Ana Arance; Vanna Chiarion-Sileni; Luc Thomas; Thierry Lesimple; Laurent Mortier; Stergios J Moschos; David Hogg; Iván Márquez-Rodas; Michele Del Vecchio; Céleste Lebbé; Nicolas Meyer; Ying Zhang; Yingjie Huang; Bijoyesh Mookerjee; Georgina V Long
Journal:  Lancet Oncol       Date:  2017-06-04       Impact factor: 41.316

7.  Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Authors:  Caroline Robert; Jean J Grob; Daniil Stroyakovskiy; Boguslawa Karaszewska; Axel Hauschild; Evgeny Levchenko; Vanna Chiarion Sileni; Jacob Schachter; Claus Garbe; Igor Bondarenko; Helen Gogas; Mario Mandalá; John B A G Haanen; Celeste Lebbé; Andrzej Mackiewicz; Piotr Rutkowski; Paul D Nathan; Antoni Ribas; Michael A Davies; Keith T Flaherty; Paul Burgess; Monique Tan; Eduard Gasal; Maurizio Voi; Dirk Schadendorf; Georgina V Long
Journal:  N Engl J Med       Date:  2019-06-04       Impact factor: 91.245

8.  Nodular melanoma: patients' perceptions of presenting features and implications for earlier detection.

Authors:  Alexander J Chamberlain; Lin Fritschi; John W Kelly
Journal:  J Am Acad Dermatol       Date:  2003-05       Impact factor: 11.527

9.  The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

Authors:  Eliezer M Van Allen; Nikhil Wagle; Antje Sucker; Daniel J Treacy; Cory M Johannessen; Eva M Goetz; Chelsea S Place; Amaro Taylor-Weiner; Steven Whittaker; Gregory V Kryukov; Eran Hodis; Mara Rosenberg; Aaron McKenna; Kristian Cibulskis; Deborah Farlow; Lisa Zimmer; Uwe Hillen; Ralf Gutzmer; Simone M Goldinger; Selma Ugurel; Helen J Gogas; Friederike Egberts; Carola Berking; Uwe Trefzer; Carmen Loquai; Benjamin Weide; Jessica C Hassel; Stacey B Gabriel; Scott L Carter; Gad Getz; Levi A Garraway; Dirk Schadendorf
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

10.  Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

Authors:  Frank Stephen Hodi; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Charles Lance Cowey; Christopher D Lao; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier Francesco Ferrucci; Michael Smylie; Andrew Hill; David Hogg; Ivan Marquez-Rodas; Joel Jiang; Jasmine Rizzo; James Larkin; Jedd D Wolchok
Journal:  Lancet Oncol       Date:  2018-10-22       Impact factor: 41.316

View more
  3 in total

1.  Association of Elevated Expression Levels of COL4A1 in Stromal Cells with an Immunosuppressive Tumor Microenvironment in Low-Grade Glioma, Pancreatic Adenocarcinoma, Skin Cutaneous Melanoma, and Stomach Adenocarcinoma.

Authors:  Hyo-Jae Shin; Minchan Gil; Im-Soon Lee
Journal:  J Pers Med       Date:  2022-03-28

2.  A network pharmacology approach to evaluate the synergistic effect of dihydromyricetin and myricitrin in vine tea on the proliferation of B16F10 cells.

Authors:  Nanxing Zhao; Hongming Kong; Hesheng Liu; Qing Shi; Xiangyang Qi; Qiuping Chen
Journal:  Front Nutr       Date:  2022-09-08

3.  Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications.

Authors:  Zhiyang Zhou; Bi Peng; Juanni Li; Kewa Gao; Yuan Cai; Zhijie Xu; Yuanliang Yan
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.